title: Temozolomide for high grade glioma.
abstract: BACKGROUND
  High grade glioma (HGG) is an aggressive form of brain cancer. Treatment of HGG usually entails biopsy, or resection if safe, followed by radiotherapy. Temozolomide is a novel oral chemotherapy drug that penetrates into the brain and purportedly has a low incidence of adverse events.
  
  
  OBJECTIVE
  To assess whether temozolomide has any advantage for treating HGG in either primary or recurrent disease settings.
  
  
  METHODS
  The following databases were searched: CENTRAL (Issue 10, 2012), MEDLINE, EMBASE, Science Citation Index, Physician Data Query and the Meta-Register of Controlled Trials in October, 2012. Reference lists of identified studies were searched. The Journal of Neuro-Oncology and Neuro-oncology were handsearched from 1999 to 2012 including conference abstracts. We contacted neuro-oncologists regarding ongoing and unpublished trials.
  
  
  METHODS
  Randomised controlled trials (RCTs) where the interventions were the use of temozolomide during primary therapy or for recurrent disease. Comparisons included no chemotherapy, non-temozolomide chemotherapy or different dosing schedules of temozolomide. Patients included those of all ages with histologically proven HGG.
  
  
  METHODS
  Two review authors undertook the quality assessment and data extraction. Outcome measures included: overall survival (OS); progression-free survival (PFS); quality of life (QoL); and adverse events.
  
  
  RESULTS
  For primary therapy three RCTs were identified, enrolling a total of 745 patients, that investigated temozolomide in combination with radiotherapy versus radiotherapy alone for glioblastoma multiforme (GBM). Temozolomide increased OS (hazard ratio (HR) 0.60, 95% confidence interval (CI) 0.46 to 0.79, P value 0.0003) and increased PFS (HR 0.63, 95% CI 0.43 to 0.92, P value 0.02), when compared with radiotherapy alone, although these benefits only appear to emerge when therapy is given in both concomitant and adjuvant phases of treatment. A single RCT found that temozolomide did not have a statistically significant effect on QoL. Risk of haematological complications, fatigue and infections were increased with temozolomide.In recurrent HGG, two RCTs enrolling 672 patients in total found that temozolomide did not increase OS compared to standard chemotherapy (HR 0.9, 95% CI 0.76 to 1.06, P value 0.2) but it did increase PFS in a subgroup analysis of grade IV GBM tumours (HR 0.68, 95% CI 0.51 to 0.90, P value 0.008). Adverse events were similar between arms.In the elderly, 2 RCTs of 664 patients found OS and PFS was similar with temozolomide alone versus radiotherapy alone. QoL did not appear to differ between arms in a single trial but certain adverse events were significantly more common with temozolomide.
  
  
  CONCLUSIONS
  Temozolomide when given in both concomitant and adjuvant phases is an effective primary therapy in GBM compared to radiotherapy alone. It prolongs survival and delays progression without impacting on QoL but it does increase early adverse events. In recurrent GBM, temozolomide compared with standard chemotherapy improves time-to-progression (TTP) and may have benefits on QoL without increasing adverse events but it does not improve overall. In the elderly, temozolomide alone appears comparable to radiotherapy in terms of OS and PFS but with a higher instance of adverse events.
authors: Academic Division of Neurosurgery, Department of Clinical Neurosciences, Department of Neurosurgery, Cambridge, UK. mikehart82@me.com.
authors: Michael G
authors: MG
authors: Hart
authors: Ruth
authors: R
authors: Garside
authors: Gabriel
authors: G
authors: Rogers
authors: Ken
authors: K
authors: Stein
authors: Robin
authors: R
authors: Grant
mesh_terms: D000367:Age Factors; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005909:Glioblastoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D006801:Humans; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide
references: Control Clin Trials. 1986 Sep;7(3):177-88
references: 3802833
references: J Clin Oncol. 2000 Apr;18(7):1481-91
references: 10735896
references: Curr Opin Oncol. 2004 Nov;16(6):593-600
references: 15627023
references: Cancer Chemother Pharmacol. 1997;40(6):484-8
references: 9332462
references: Lancet Oncol. 2012 Sep;13(9):916-26
references: 22877848
references: J Clin Oncol. 2009 Aug 10;27(23):3861-7
references: 19506159
references: Cochrane Database Syst Rev. 2019 Jun 06;6:CD002034
references: 31169915
references: BMJ. 1991 May 11;302(6785):1136-40
references: 2043787
references: J Neurooncol. 2011 Jul;103(3):595-602
references: 21052775
references: N Engl J Med. 2007 Apr 12;356(15):1527-35
references: 17429084
references: Br J Cancer. 2000 Sep;83(5):588-93
references: 10944597
references: Cochrane Database Syst Rev. 2008 Oct 08;(4):CD007415
references: 18843749
references: J Neurol Neurosurg Psychiatry. 2004 Jun;75 Suppl 2:ii18-23
references: 15146035
references: J Clin Oncol. 2005 Apr 1;23(10):2372-7
references: 15800329
references: Arch Pathol Lab Med. 2003 Feb;127(2):187-92
references: 12562232
references: J Clin Oncol. 2006 Jun 20;24(18):2707-14
references: 16782910
references: J Neurol Neurosurg Psychiatry. 2004 Jun;75 Suppl 2:ii24-30
references: 15146036
references: Curr Opin Neurol. 2008 Dec;21(6):745-53
references: 18989121
references: Neuroepidemiology. 2004 Jan-Apr;23(1-2):85-93
references: 14739573
references: Acta Neuropathol. 2007 Aug;114(2):97-109
references: 17618441
references: BMJ. 2001 Jul 7;323(7303):42-6
references: 11440947
references: Cochrane Database Syst Rev. 2002;(4):CD003913
references: 12519620
references: Strahlenther Onkol. 2008 Nov;184(11):572-9
references: 19016015
references: Neuro Oncol. 2011 Jan;13(1):132-42
references: 20980335
references: J Clin Oncol. 2009 Dec 10;27(35):5874-80
references: 19901110
references: Lancet Oncol. 2009 May;10(5):459-66
references: 19269895
references: Brain Pathol. 1993 Jul;3(3):255-68
references: 8293185
references: Zhonghua Yi Xue Za Zhi. 2009 Aug 4;89(29):2059-62
references: 20017331
references: J Clin Oncol. 2010 Oct 20;28(30):4601-8
references: 20855843
references: Lancet Oncol. 2012 Jul;13(7):707-15
references: 22578793
references: Cochrane Database Syst Rev. 2011 Mar 16;(3):CD007294
references: 21412902
references: CNS Drugs. 2007;21(9):775-87
references: 17696576
references: Anticancer Res. 2003 Nov-Dec;23(6D):5159-64
references: 14981983
references: J Neurooncol. 2003 Jun;63(2):179-86
references: 12825822
references: Lancet Oncol. 2005 Dec;6(12):937-44
references: 16321761
references: J Clin Oncol. 2002 Mar 1;20(5):1375-82
references: 11870182
references: Eur J Cancer. 2000 Sep;36(14):1788-95
references: 10974627
references: J Clin Oncol. 1999 Sep;17(9):2762-71
references: 10561351
references: J Neurooncol. 2017 Jan;131(1):193-199
references: 27770279
references: J Neurosurg. 1978 Sep;49(3):333-43
references: 355604
references: J Clin Oncol. 2009 Mar 10;27(8):1268-74
references: 19204207
references: J Clin Oncol. 2006 Jun 20;24(18):2715-22
references: 16782911
references: J Clin Oncol. 2010 Apr 10;28(11):1963-72
references: 20231676
references: J Neurol Neurosurg Psychiatry. 1996 Aug;61(2):143-50
references: 8708681
references: Eur J Cancer. 1996 Dec;32A(13):2236-41
references: 9038604
references: Stat Med. 1998 Dec 30;17(24):2815-34
references: 9921604
references: Cancer Treat Rev. 2006 Oct;32(6):483-6
references: 16730911
references: N Engl J Med. 2005 Mar 10;352(10):987-96
references: 15758009
references: J Neurooncol. 2004 Feb;66(3):351-60
references: 15015668